Filter by audience:
Oral sessions summaries
DFN-15 (Celecoxib Oral Solution, 25 Mg/ml) in the Acute Treatment of Episodic Migraine: Efficacy Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetic, and Drug-drug Interaction Study with Lasmiditan
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Rimegepant 75 mg Provides Early and Sustained Relief of Migraine with a Single Oral Dose: Results from 3 Phase 3 Clinical Trials
AHSAM 2020 - Oral session
Published on September 11, 2020
Identify Biomarkers in Migraine and Cluster Headache by Improving Experimental Design
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Wolff Award: Cognitive Networks Disarrangement in Patients with Migraine Predicts Cutaneous Allodynia
AHSAM 2020 - Oral session
Published on July 17, 2020
Early Career Award: Alterations in Functional Connectivity during Different Phases of the Triggered Migraine Attack
AHSAM 2020 - Oral session
Published on July 17, 2020
Solomon Award Lecture: Observations 2020 - 'Teaching Headache'
AHSAM 2020 - Oral session
Published on July 17, 2020
Graham Award: Practical Approach to Eye Pain and Photophobia
AHSAM 2020 - Oral session
Published on July 17, 2020
Headache & COVID-19: A Short-term Challenge with Long-term Insights
AHSAM 2020 - Oral session
Published on July 17, 2020
COVID-19 and Headache: The New York Experience
AHSAM 2020 - Oral session
Published on July 17, 2020
Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers
AHSAM 2020 - Oral session
Published on July 17, 2020
A Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
AHSAM 2020 - Oral session
Published on July 30, 2020
Endogenous Analgesia in Patients with Chronic Migraine: A Study of Conditioned Pain Modulation
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Exploring the Boundaries Between Episodic and Chronic Migraine: Results from the CaMEO Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Efficacy and Tolerability of CGRP Monoclonal Antibody Medications in Patients with Chronic Migraine Undergoing Treatment with OnabotulinumtoxinA
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Inter and Intra-individual Differences in the Association Between Menstruation and Migraine
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Role of PAR-2 Receptors in Migraine Using a Novel, Translatable Injury-Free Preclinical Model
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Sustained Efficacy and Safety of Erenumab in Patients with Episodic Migraine who Failed 2–4 Prior Preventive Treatments: 2-year Interim Results of the LIBERTY Open-label Extension Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Trainee Headache and Education Management (THEME) Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Real World Efficacy, Tolerability and Safety Study of Ubrogepant, Rimegepant, and Lasmiditan
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Correlation of Pediatric Headache-related Functional Disability Inventory (FDI) and Prolonged School Absence
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Retrospective Review of the Use of Anti-CGRP Monoclonal Antibodies to Treat Headaches in Patients with Idiopathic Intracranial Hypertension
AHSAM 2020 - Oral session
Published on July 30, 2020
The Role of Cerebellar CGRP in Migraine-like Behavior
AHSAM 2020 - Oral session
Published on July 23, 2020
Characteristics of Individuals with Migraine Who Are Eligible for Novel CGRP Monoclonal Antibodies: Results of the OVERCOME Study
AHSAM 2020 - Oral session
Published on July 30, 2020
Multiple, Once-daily, Oral Doses of 170 Mg Atogepant for 28 Days Are Safe and Well Tolerated with No Clinically Significant Effect on Alanine Aminotransferase in Healthy Adults
AHSAM 2020 - Oral session
Published on September 3, 2020
Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2
AHSAM 2020 - Oral session
Published on September 3, 2020
Survivors of Military Sexual Trauma Face Increased risk of Migraine Headaches and Worse Headache Care
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Improved Functionality, Satisfaction, and Global Impression of Change with Ubrogepant for the Acute Treatment of Migraine in Triptan Insufficient Responders
AHSAM 2020 - Oral session
Published on September 11, 2020
Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3 Trial
AHSAM 2020 - Oral session
Published on September 11, 2020
Identifying Barriers to Care-seeking, Diagnosis, and Preventive Medication Among Those with Migraine: Results of the OVERCOME Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Real-World Experience with Calcitonin Gene-related Peptide (CGRP) Antagonists in the Treatment of Migraine
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Consistency of the Efficacy of Single Use and Repeated Use of M207 (Intracutaneous Microneedle Zolmitriptan) for the Acute Treatment of Migraine; Results for Pain Freedom, Pain Relief, and Sustained Pain Freedom and Pain Relief
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Pooled Analysis of Cardiovascular Safety with Fremanezumab Treatment in Patients with Migraine by Number of Cardiovascular or Cerebrovascular Risk Factors
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
A Real-World Comparison of Erenumab and Galcanezumab in a Tertiary Headache Center
AHSAM 2020 - Oral session
Published on September 17, 2020
The Impact of Migraine on Pregnancy Plan: Insights from the American Registry for Migraine Research (ARMR)
AHSAM 2020 - Oral session
Published on September 24, 2020 | NEW
Prevalence of Headache and Comorbidities Among Men and Women Veterans Across the Veterans Health Administration – a 10-year Cohort Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Migraine as a Risk Factor for Dementia: A National Register-based Follow-up Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Development of a Visualization Tool for Tracking Modifiable Risk Factors for Progression from Episodic to Chronic Migraine
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Improving Headache Management in the Pediatric Emergency Department
AHSAM 2020 - Oral session
Published on July 30, 2020
Childhood and Adolescent Migraine Prevention [CHAMP] Trial: The 3-year Follow-up Survey Results
AHSAM 2020 - Oral session
Published on July 30, 2020
Improving Headache Management in the Pediatric Emergency Department
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Exploring Naturally Occurring Clinical Subgroups of Post-traumatic Headache
AHSAM 2020 - Oral session
Published on July 23, 2020
Effects of Pre-injury Migraine Frequency on Post-traumatic Headache Recovery in the General Adult Population: The Toronto Concussion Study
AHSAM 2020 - Oral session
Published on July 23, 2020
Mild TBI induces long-lasting sensitization to pain in mice
AHSAM 2020 - Oral session
Published on August 27, 2020
